Knight Therapeutics (TSE:GUD)
TSX:GUD
Want to see TSE:GUD full AI Analyst Report?
Total Valuation
Knight Therapeutics has a market cap or net worth of C$920.92M. The enterprise value is C$764.63M.
Market CapC$920.92M
Enterprise ValueC$764.63M
Share Statistics
Knight Therapeutics has 98,179,360 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding98,179,360
Owned by Insiders23.45%
Owned by Institutions0.09%
Financial Efficiency
Knight Therapeutics’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -0.20%.
Return on Equity (ROE)>-0.01
Return on Assets (ROA)>-0.01
Return on Invested Capital (ROIC)-0.20%
Return on Capital Employed (ROCE)>-0.01
Revenue Per Employee604.14K
Profits Per Employee-7.21K
Employee Count745
Asset Turnover0.43
Inventory Turnover2.20
Valuation Ratios
The current PE Ratio of Knight Therapeutics is 164.6. Knight Therapeutics’s PEG ratio is 0.50.
PE Ratio164.6
PS Ratio1.34
PB Ratio0.79
Price to Fair Value0.79
Price to FCF8.81
Price to Operating Cash Flow8.75
PEG Ratio0.50
Income Statement
In the last 12 months, Knight Therapeutics had revenue of 450.09M and earned -5.37M in profits. Earnings per share was -0.05.
Revenue450.09M
Gross Profit150.74M
Operating Income-2.20M
Pretax Income-6.70M
Net Income-5.37M
EBITDA54.37M
Earnings Per Share (EPS)-0.05
Cash Flow
In the last 12 months, operating cash flow was 105.56M and capital expenditures -29.37M, giving a free cash flow of 76.19M billion.
Operating Cash Flow105.56M
Free Cash Flow76.19M
Free Cash Flow per Share0.78
Dividends & Yields
Knight Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.37
52-Week Price Change55.56%
50-Day Moving Average7.99
200-Day Moving Average6.58
Relative Strength Index (RSI)76.50
Average Volume (3m)48.52K
Important Dates
Knight Therapeutics upcoming earnings date is Aug 6, 2026, Before Open (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Knight Therapeutics as a current ratio of 2.39, with Debt / Equity ratio of 8.86%
Current Ratio2.39
Quick Ratio1.57
Debt to Market Cap0.12
Net Debt to EBITDA0.03
Interest Coverage Ratio-0.21
Taxes
In the past 12 months, Knight Therapeutics has paid -1.33M in taxes.
Income Tax-1.33M
Effective Tax Rate0.20
Enterprise Valuation
Knight Therapeutics EV to EBITDA ratio is 11.11, with an EV/FCF ratio of 8.83.
EV to Sales1.34
EV to EBITDA11.11
EV to Free Cash Flow8.83
EV to Operating Cash Flow8.59
Balance Sheet
Knight Therapeutics has C$127.29M in cash and marketable securities with C$69.78M in debt, giving a net cash position of C$57.52M billion.
Cash & Marketable SecuritiesC$127.29M
Total DebtC$69.78M
Net CashC$57.52M
Net Cash Per ShareC$0.59
Tangible Book Value Per ShareC$2.99
Margins
Gross margin is 37.32%, with operating margin of -0.49%, and net profit margin of -1.19%.
Gross Margin37.32%
Operating Margin-0.49%
Pretax Margin-1.49%
Net Profit Margin-1.19%
EBITDA Margin12.08%
EBIT Margin-0.49%
Analyst Forecast
The average price target for Knight Therapeutics is C$9.61, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetC$9.61
Price Target Upside25.65% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast36.93%
EPS Growth Forecast-47.43%